LONG FACTOR CERTIFICATE - UCB Stock

YPK5H

DE000GQ6CWC6

Market Closed - Euronext Paris 12:30:02 2024-06-21 pm EDT
219.9 ^EUR	+19.20%

Current month	+86.51%
1 month	+82.90%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart UCB

Latest news about UCB

UCB Launches Dravet Syndrome Sound of Profound Moments: Family Video Project	Jun. 20	BU
Kepler Cheuvreux Downgrades UCB to Hold from Buy, Raises PT	Jun. 20	MT
UCB : Financial Reporting Document	Jun. 15	PU
UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels	Jun. 13	CI

More news

Quotes 5-day view

Date	Price	Change
24-06-21	219.6	+19.08%
24-06-20	184.4	-22.31%
24-06-19	237.4	+1.60%
24-06-18	233.7	+10.10%
24-06-17	212.2	-3.62%

Real-time Euronext Paris

Last update June 21, 2024 at 12:30 pm EDT

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	UCB
Issuer	Goldman Sachs
	YPK5H
ISIN	DE000GQ6CWC6
Date issued	2023-09-28
Strike	123.2 €
Maturity	Unlimited
Parity	0.08 : 1
Emission price	9.99 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	240.1 €
Lowest since issue	1.01 €
Spread	7 €
Spread %	3.13%

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

More about the company

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: UCB

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

139.1 EUR

Average target price

135.5 EUR

Spread / Average Target

-2.59%

Consensus